Cargando…
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard‐of‐care for the treatment of a wide variety of solid neoplasms. However, tumour responses remain unpredictable, experienced by only a minority of ICI recipients across malignancy types. Therefore, there is an urgen...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320825/ https://www.ncbi.nlm.nih.gov/pubmed/35394069 http://dx.doi.org/10.1002/path.5907 |
_version_ | 1784755886517911552 |
---|---|
author | Gunjur, Ashray Manrique‐Rincón, Andrea J Klein, Oliver Behren, Andreas Lawley, Trevor D Welsh, Sarah J Adams, David J |
author_facet | Gunjur, Ashray Manrique‐Rincón, Andrea J Klein, Oliver Behren, Andreas Lawley, Trevor D Welsh, Sarah J Adams, David J |
author_sort | Gunjur, Ashray |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard‐of‐care for the treatment of a wide variety of solid neoplasms. However, tumour responses remain unpredictable, experienced by only a minority of ICI recipients across malignancy types. Therefore, there is an urgent need for better predictive biomarkers to identify a priori the patients most likely to benefit from these therapies. Despite considerable efforts, only three such biomarkers are FDA‐approved for clinical use, and all rely on the availability of tumour tissue for immunohistochemical staining or genomic assays. There is emerging evidence that host factors – for example, genetic, metabolic, and immune factors, as well as the composition of one's gut microbiota – influence the response of a patient's cancer to ICIs. Tantalisingly, some of these factors are modifiable, paving the way for co‐therapies that may enhance the therapeutic index of these treatments. Herein, we review key host factors that are of potential biomarker value for response to ICI therapy, with a particular focus on the proposed mechanisms for these influences. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. |
format | Online Article Text |
id | pubmed-9320825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-93208252022-07-30 ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors Gunjur, Ashray Manrique‐Rincón, Andrea J Klein, Oliver Behren, Andreas Lawley, Trevor D Welsh, Sarah J Adams, David J J Pathol Invited Reviews Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard‐of‐care for the treatment of a wide variety of solid neoplasms. However, tumour responses remain unpredictable, experienced by only a minority of ICI recipients across malignancy types. Therefore, there is an urgent need for better predictive biomarkers to identify a priori the patients most likely to benefit from these therapies. Despite considerable efforts, only three such biomarkers are FDA‐approved for clinical use, and all rely on the availability of tumour tissue for immunohistochemical staining or genomic assays. There is emerging evidence that host factors – for example, genetic, metabolic, and immune factors, as well as the composition of one's gut microbiota – influence the response of a patient's cancer to ICIs. Tantalisingly, some of these factors are modifiable, paving the way for co‐therapies that may enhance the therapeutic index of these treatments. Herein, we review key host factors that are of potential biomarker value for response to ICI therapy, with a particular focus on the proposed mechanisms for these influences. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2022-05-20 2022-07 /pmc/articles/PMC9320825/ /pubmed/35394069 http://dx.doi.org/10.1002/path.5907 Text en © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Invited Reviews Gunjur, Ashray Manrique‐Rincón, Andrea J Klein, Oliver Behren, Andreas Lawley, Trevor D Welsh, Sarah J Adams, David J ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title | ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title_full | ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title_fullStr | ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title_full_unstemmed | ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title_short | ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
title_sort | ‘know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors |
topic | Invited Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320825/ https://www.ncbi.nlm.nih.gov/pubmed/35394069 http://dx.doi.org/10.1002/path.5907 |
work_keys_str_mv | AT gunjurashray knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT manriquerinconandreaj knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT kleinoliver knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT behrenandreas knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT lawleytrevord knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT welshsarahj knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors AT adamsdavidj knowthyselfhostfactorsinfluencingcancerresponsetoimmunecheckpointinhibitors |